Previous 10 | Next 10 |
home / stock / azn / azn articles
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small ...
As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc's (NYSE: PFE) vaccine, Ab...
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this artic...
AstraZeneca Plc's (NASDAQ: AZN) supplemental New Drug Application for Tagrisso (osimertinib) in combination with chemotherapy has been acc...
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of ...
Benzinga Microsoft's Nadella Criticizes Google's Exclusive Content Deals Amid Antitrust Case In a significant development, Microsoft ...
ALX Oncology Holdings Inc (NASDAQ: ALXO) released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cy...
AstraZeneca Plc (NASDAQ: AZN) has agreed to pay $425 million to settle U.S. lawsuits related to heartburn and stomach acid treatment...
A U.S. District Judge has upheld a pivotal initiative of President Joe Biden, giving the green light for Medicare to commence negotiations on ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-20 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 08:30:07 ET Jefferies analyst issues HOLD recommendation for AZN on July 2, 2024 06:20AM ET. The previous analyst recommendation was Hold. AZN was trading at $77.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...